vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and Snail, Inc. (SNAL). Click either name above to swap in a different company.
Snail, Inc. is the larger business by last-quarter revenue ($25.1M vs $18.7M, roughly 1.3× CytomX Therapeutics, Inc.). CytomX Therapeutics, Inc. runs the higher net margin — -0.8% vs -3.4%, a 2.6% gap on every dollar of revenue. On growth, Snail, Inc. posted the faster year-over-year revenue change (-4.2% vs -25.7%). Over the past eight quarters, Snail, Inc.'s revenue compounded faster (33.4% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Suzhou Snail Digital Technology Co., Ltd., doing business as Snail, is a Chinese video game company and a Virtual Network Operator headquartered in Suzhou, China, which has branches Snail Games and Snail Mobile. Its division, Snail USA, markets Snail Games products in North America, South America, & Europe. Snail Games products include massively multiplayer online (MMOs), real-time strategy (RTS), and casual games. Its global registered user base has reached over 70 million accounts. The U.S....
CTMX vs SNAL — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $25.1M |
| Net Profit | $-154.0K | $-862.2K |
| Gross Margin | — | 38.3% |
| Operating Margin | -6.9% | -6.0% |
| Net Margin | -0.8% | -3.4% |
| Revenue YoY | -25.7% | -4.2% |
| Net Profit YoY | 97.6% | -177.0% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $25.1M | ||
| Q3 25 | — | $13.8M | ||
| Q2 25 | $18.7M | $22.2M | ||
| Q1 25 | $50.9M | $20.1M | ||
| Q4 24 | $38.1M | $26.2M | ||
| Q3 24 | $33.4M | $22.5M | ||
| Q2 24 | $25.1M | $21.6M | ||
| Q1 24 | $41.5M | $14.1M |
| Q4 25 | — | $-862.2K | ||
| Q3 25 | — | $-7.9M | ||
| Q2 25 | $-154.0K | $-16.6M | ||
| Q1 25 | $23.5M | $-1.9M | ||
| Q4 24 | $18.9M | $1.1M | ||
| Q3 24 | $5.7M | $235.1K | ||
| Q2 24 | $-6.5M | $2.3M | ||
| Q1 24 | $13.8M | $-1.8M |
| Q4 25 | — | 38.3% | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | 31.3% | ||
| Q1 25 | — | 29.1% | ||
| Q4 24 | — | 43.3% | ||
| Q3 24 | — | 38.6% | ||
| Q2 24 | — | 37.5% | ||
| Q1 24 | — | 14.7% |
| Q4 25 | — | -6.0% | ||
| Q3 25 | — | -71.3% | ||
| Q2 25 | -6.9% | -8.2% | ||
| Q1 25 | 44.4% | -20.4% | ||
| Q4 24 | 46.4% | 11.5% | ||
| Q3 24 | 12.3% | 1.8% | ||
| Q2 24 | -33.7% | 12.4% | ||
| Q1 24 | 28.1% | -15.6% |
| Q4 25 | — | -3.4% | ||
| Q3 25 | — | -56.9% | ||
| Q2 25 | -0.8% | -74.7% | ||
| Q1 25 | 46.2% | -9.7% | ||
| Q4 24 | 49.6% | 4.3% | ||
| Q3 24 | 17.2% | 1.0% | ||
| Q2 24 | -26.0% | 10.4% | ||
| Q1 24 | 33.3% | -12.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-0.44 | ||
| Q1 25 | — | $-0.06 | ||
| Q4 24 | — | $0.03 | ||
| Q3 24 | — | $0.01 | ||
| Q2 24 | — | $0.06 | ||
| Q1 24 | — | $-0.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $8.6M |
| Total DebtLower is stronger | — | $14.6M |
| Stockholders' EquityBook value | $119.9M | $-16.4M |
| Total Assets | $175.1M | $59.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $8.6M | ||
| Q3 25 | — | $12.3M | ||
| Q2 25 | $49.0M | $7.9M | ||
| Q1 25 | $47.6M | $9.4M | ||
| Q4 24 | $38.1M | $7.3M | ||
| Q3 24 | $40.6M | $10.6M | ||
| Q2 24 | $43.2M | $15.5M | ||
| Q1 24 | $36.2M | $16.1M |
| Q4 25 | — | $14.6M | ||
| Q3 25 | — | $10.5M | ||
| Q2 25 | — | $11.8M | ||
| Q1 25 | — | $9.0M | ||
| Q4 24 | — | $5.7M | ||
| Q3 24 | — | $5.7M | ||
| Q2 24 | — | $5.8M | ||
| Q1 24 | — | $6.5M |
| Q4 25 | — | $-16.4M | ||
| Q3 25 | — | $-15.6M | ||
| Q2 25 | $119.9M | $-8.0M | ||
| Q1 25 | $25.0M | $9.1M | ||
| Q4 24 | $-456.0K | $9.7M | ||
| Q3 24 | $-23.5M | $8.2M | ||
| Q2 24 | $-31.2M | $7.9M | ||
| Q1 24 | $-31.7M | $5.6M |
| Q4 25 | — | $59.3M | ||
| Q3 25 | — | $51.1M | ||
| Q2 25 | $175.1M | $58.0M | ||
| Q1 25 | $98.5M | $64.5M | ||
| Q4 24 | $120.5M | $62.2M | ||
| Q3 24 | $139.0M | $66.8M | ||
| Q2 24 | $159.2M | $75.4M | ||
| Q1 24 | $184.7M | $78.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.99× | ||
| Q4 24 | — | 0.59× | ||
| Q3 24 | — | 0.70× | ||
| Q2 24 | — | 0.73× | ||
| Q1 24 | — | 1.16× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $-5.3M |
| Free Cash FlowOCF − Capex | $-15.8M | — |
| FCF MarginFCF / Revenue | -84.6% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-5.3M | ||
| Q3 25 | — | $6.6M | ||
| Q2 25 | $-15.8M | $-3.2M | ||
| Q1 25 | $-21.0M | $764.5K | ||
| Q4 24 | $-19.9M | $-3.6M | ||
| Q3 24 | $-20.7M | $-5.0M | ||
| Q2 24 | $-19.5M | $206.6K | ||
| Q1 24 | $-26.0M | $6.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-15.8M | — | ||
| Q1 25 | $-21.2M | — | ||
| Q4 24 | $-20.0M | — | ||
| Q3 24 | $-20.7M | — | ||
| Q2 24 | $-19.6M | — | ||
| Q1 24 | $-26.2M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -84.6% | — | ||
| Q1 25 | -41.6% | — | ||
| Q4 24 | -52.5% | — | ||
| Q3 24 | -62.1% | — | ||
| Q2 24 | -78.2% | — | ||
| Q1 24 | -63.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 0.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | -3.21× | ||
| Q3 24 | -3.61× | -21.05× | ||
| Q2 24 | — | 0.09× | ||
| Q1 24 | -1.89× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
SNAL
| Pc | $14.7M | 59% |
| Platform Three | $5.2M | 21% |
| Platform Two | $3.3M | 13% |
| Sales Channel Directly To Consumer Mobile Sale | $1.6M | 6% |
